What is the appropriate evaluation and management of a woman presenting with metrorrhagia?

Evaluation and Management of Metrorrhagia

Begin evaluation with a thorough history focusing on bleeding pattern, age, and risk factors for endometrial cancer, followed by pelvic examination and transvaginal ultrasound as the primary imaging modality to identify structural causes. 1

Initial Assessment

History and Physical Examination

• Document bleeding characteristics: regularity, volume, frequency, duration, presence of clots ≥1 inch diameter, and "flooding" (changing pad/tampon more frequently than hourly) 2
• Assess age and reproductive status: Women ≥35 years with recurrent anovulation or women <35 years with endometrial cancer risk factors require endometrial biopsy 3
• Screen for bleeding disorders: Personal or family history of bleeding, especially if accompanied by flooding and/or prolonged menses, warrants hematology referral 2
• Evaluate for systemic causes: thyroid dysfunction, diabetes mellitus, hyperprolactinemia, coagulopathies (particularly von Willebrand disease), and medication use (antipsychotics, antiepileptics, anticoagulants) 3, 2

Laboratory Evaluation

• Complete blood count to assess for anemia 2
• Thyroid function tests 3
• Coagulation studies if bleeding disorder suspected 2
• Pregnancy test to exclude pregnancy 4

Imaging Strategy

First-Line Imaging

• Transvaginal ultrasound (TVUS) is the primary imaging modality for evaluating structural causes of abnormal uterine bleeding 1
• Saline infusion sonohysterography provides superior visualization of endometrial polyps and submucosal fibroids compared to standard TVUS 3, 5
• 3-D ultrasound may be considered for spatial assessment of leiomyomas and other uterine pathologies 1

Advanced Imaging

• MRI with diffusion-weighted imaging should be obtained when:
  • TVUS cannot completely visualize the endometrium due to patient body habitus, uterine position, or presence of leiomyomas/adenomyosis 1
  • Differentiation between benign and malignant lesions is needed 1
  • Pre-procedural planning for uterine artery embolization is required 1

Endometrial Sampling Indications

• Women ≥35 years with recurrent anovulation 3
• Women <35 years with risk factors for endometrial cancer 3
• Any woman with excessive bleeding unresponsive to medical therapy 3
• When TVUS cannot adequately assess the endometrium 1

Management Algorithm

Medical Management (First-Line)

For Anovulatory Bleeding:

• Combination oral contraceptives or cyclic progestins to regulate menstrual cycles 3
• Continuous progestin therapy for hyperplasia without atypia 3
• Referral to gynecologist for hyperplasia with atypia; gynecologic oncologist for adenocarcinoma 3

For Ovulatory Bleeding (Menorrhagia):

• Levonorgestrel-releasing intrauterine system (IUS) is highly effective, with efficacy comparable to endometrial ablation or hysterectomy 5
• Tranexamic acid reduces menstrual blood loss by 20-60% and is FDA-approved for ovulatory bleeding 3, 5
• NSAIDs reduce menstrual blood loss by 20-60% 5
• Oral contraceptives are effective 5
• Note: Cyclic progestogens do NOT significantly reduce bleeding in women who ovulate 5

Surgical Management (When Medical Therapy Fails)

Proceed to surgical intervention when:

• Clear structural causes are identified (polyps, fibroids) 3
• Medical management is ineffective 3

Surgical options include:

• Polypectomy or fibroidectomy for focal lesions 3
• Uterine artery embolization for leiomyomas 3
• Endometrial ablation for diffuse disease 3
• Hysterectomy as the most definitive treatment 3

Critical Pitfalls to Avoid

• Do not miss endometrial cancer: In premenopausal women aged 40-50 years, there is much higher prevalence of myomas, adenomyosis, and dysfunctional endometrium (including hyperplasia and neoplasia), emphasizing the importance of accurate diagnosis in this age group 4
• Do not assume cyclic progestins work for ovulatory bleeding: They are ineffective in women who ovulate 5
• Do not delay hematology referral: Women with flooding, prolonged menses, or personal/family bleeding history likely have an underlying bleeding disorder 2
• Do not rely solely on patient-reported blood loss: Subjective assessment does not reflect true menstrual blood loss 5
• Do not overlook incomplete TVUS evaluation: When adenomyosis or leiomyomas prevent complete endometrial visualization, proceed to MRI or endometrial sampling based on cancer risk 1